Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 6Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Dermatologic 1Breast 1

Conditions

Melanoma 241Carcinoma, Non-Small-Cell Lung 56Carcinoma, Renal Cell 40Skin Neoplasms 39Uveal Melanoma 31Squamous Cell Carcinoma of Head and Neck 30Neoplasms 30Colorectal Neoplasms 27Sarcoma 25Neoplasm Metastasis 25Carcinoma, Merkel Cell 24Ovarian Neoplasms 23Lung Neoplasms 22Stomach Neoplasms 21Carcinoma, Basal Cell 21Breast Neoplasms 20Head and Neck Neoplasms 18Esophageal Neoplasms 16Uterine Cervical Neoplasms 15Pancreatic Neoplasms 15Carcinoma, Hepatocellular 15Lymphoma, T-Cell, Cutaneous 14Urinary Bladder Neoplasms 13Triple Negative Breast Neoplasms 13Prostatic Neoplasms 13Carcinoma, Transitional Cell 13Brain Neoplasms 13Thyroid Neoplasms 11Small Cell Lung Carcinoma 10Mycosis Fungoides 10

Interventions

Prednisone 1Methylprednisolone Hemisuccinate 1Methylprednisolone 1Infliximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Drug-Related Side Effects and Adverse Reactions × Dermatologic × Clear all
NCT04305145 2026-01-29

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

Massachusetts General Hospital

Phase 2 Active not recruiting
42 enrolled
Dermatologic

Colitis, Melanoma, Skin Neoplasms, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡